NPY and ovarian cancer: For the treatment of cancer, several cancer-specific receptors or markers are targeted by PDCs such as the integrin (αvβ3) receptor for ovarian cancer, EGFR receptor and MUC1 (CD227) for lung, breast, bladder, and ovarian cancer, NPY(Hy1R) receptor for breast cancer and Ewing sarcoma, and MC1R receptor for melanoma (REFS) [154,155,156].